Anthrax Treatment Market – Type (Inhalation, Cutaneous, Gastrointestinal, Injection), Drug Class (Antibiotics, Immunoglobulins, Combination Therapy), Route of Administration (Parenteral, Oral), Distribution Channel & Forecast (2024 – 2032)

Anthrax Treatment Market Size

Anthrax Treatment Market size was valued at USD 364.4 million in 2023 and is projected to witness over 7.9% CAGR over the forecast period. Advancements in biotechnology and drug development are shaping the market. Innovations such as the development of monoclonal antibodies, like raxibacumab and obiltoxaximab, specifically target anthrax toxins and have enhanced treatment efficacy.

Additionally, ongoing research is leading to the discovery of new antibiotics that can effectively combat Bacillus anthracis, addressing concerns related to antibiotic resistance. These advancements are improving therapeutic options and expanding the arsenal available to treat anthrax infections. Furthermore, the rising incidence of zoonotic diseases, including anthrax, is a significant driver in the anthrax treatment market. The increasing interaction between humans and animals, especially in agricultural and rural settings, has led to a higher risk of zoonotic disease outbreaks. This has heightened the need for effective anthrax treatments, thereby propelling market growth.
 

Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. Anthrax can manifest in different forms, depending on the route of infection: cutaneous, inhalational, gastrointestinal, and injectional. Anthrax treatment refers to the medical management and therapeutic interventions aimed at addressing infection caused by Bacillus anthracis.
 

Anthrax Treatment Market Trends

• Increasing demand for effective anthrax treatment is a significant driver in the anthrax treatment industry, propelled by heightened awareness of bioterrorism threats, growing prevalence of zoonotic diseases, and the necessity for rapid and reliable responses to potential outbreaks.
   
• The recognition of anthrax as a potential bioterrorism agent, highlighted by incidents like the 2001 anthrax attacks in the U.S., has underscored the urgent need for effective treatments. Governments and public health agencies are acutely aware of the bioterrorism threat, leading to increased investments in preparedness measures, including the development and stockpiling of antibiotics, antitoxins, and vaccines. This heightened awareness has significantly driven the demand for various therapeutic options.
   
• Further, rising healthcare investments significantly drive the market by enhancing research and development, improving healthcare infrastructure, and ensuring the availability of critical treatments.
   

Anthrax Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on type, the market is segmented into inhalation anthrax, cutaneous anthrax, gastrointestinal anthrax, and injection anthrax. The inhalation anthrax segment dominated the global market in 2023 with 44.5% of market share.
 

• Inhalation anthrax is recognized as the most severe form of the disease, with a high mortality rate if left untreated. This severity necessitates immediate and aggressive treatment, driving significant investment in developing and stockpiling therapies tailored specifically for inhalation anthrax.
   
• Additionally, the potential use of anthrax as a bioweapon has led to heightened awareness and extensive government preparedness programs, resulting in substantial funding directed toward research, development, and procurement of treatments and countermeasures for inhalation anthrax. These factors collectively drive the growth of this segment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on drug class, the anthrax treatment market is classified into antibiotics, immunoglobulins, and combination therapy. The antibiotics segment held highest market share and accounted for USD 227.4 million in 2023.
 

• The dominance of the antibiotics segment in the anthrax treatment industry is driven by its pivotal role as the primary treatment modality, backed by proven efficacy, safety, and broad-spectrum activity against Bacillus anthracis.
   
• The broad-spectrum activity of antibiotics used in anthrax treatment enables them to target Bacillus anthracis as well as secondary bacterial infections, enhancing their versatility and utility. This versatility solidifies antibiotics as valuable therapeutic agents in anthrax treatment, contributing to their high market share.
   

Based on route of administration, the market is divided into parenteral and oral. Among the routes of administration, parenteral segment accounted for majority of market share and is anticipated to grow at 7.6% of CAGR.
 

• Parenteral administration allows for rapid and reliable delivery of medications directly into the bloodstream, ensuring swift action in critical situations such as anthrax infection.
   
• Additionally, parenteral routes, including intravenous and intramuscular injections, are preferred for administering antitoxins, and antibiotics in cases where oral administration may be ineffective due to gastrointestinal issues or compromised absorption.
   
• Moreover, in emergency scenarios such as anthrax outbreaks or bioterrorism incidents, parenteral administration offers the advantage of immediate treatment initiation, thereby contributing to the growth of this segment.
   

Based on distribution channel, the anthrax treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2023 and is projected to reach USD 402.3 million by 2032.
 

• Hospital pharmacies maintain a robust stock of essential antibiotics which are the frontline treatments for anthrax.
   
• Additionally, hospital pharmacies benefit from integrated healthcare systems, ensuring rapid access to diagnostic facilities and multidisciplinary medical teams for comprehensive patient care.
   
• Their ability to manage complex medication regimens and provide patient-specific therapeutic solutions further consolidates their market dominance.
   

Looking for region specific data?

Download Free PDF

North America anthrax treatment industry was valued at USD 141.7 million in 2023 and is anticipated to grow at 7.8% over the forecast timeframe.
 

• North America boasts a significant livestock population, particularly cattle, which is highly susceptible to anthrax leading to increased risk of anthrax transmission to humans, thus necessitating the effective anthrax treatment options.
   
• Additionally, advanced healthcare infrastructure in the region facilitating prompt diagnosis, treatment, and management of anthrax cases, ensuring timely and effective care for affected individuals.
   
• These factors collectively aid in driving the growth of the North America anthrax market.
   

U.S. market is predicted to experience over 7.7% CAGR and reach USD 251.4 million by 2032.
 

• Although anthrax is relatively rare, the U.S. has experienced notable anthrax outbreaks in the past, including the 2001 anthrax attacks. These incidents have heightened awareness about the threat of anthrax and underscored the importance of having effective treatments readily available, further driving the demand for anthrax treatments in the U.S.
   
• Additionally, factors such as advanced healthcare infrastructure, high research & development investments, strong emphasis on bioterrorism preparedness, presence of major pharmaceutical companies, further fosters the growth of this country.
   

Germany anthrax treatment market held a significant position in global industry.
 

• Germany is home to a robust pharmaceutical industry known for its innovation and high-quality production standards. Leading pharmaceutical companies in Germany invest significantly in research and development of new treatments for anthrax, contributing to the availability of advanced therapies and bolstering the country's position in the market.
   

India market is predicted to showcase lucrative growth during the forecast period.
 

• According to 20^th Livestock Census, total livestock population in India were 535.78 million in 2019. Of which total number of cattle in the country were 192.49 million in 2019. With this substantial livestock population, India faces heightened risks of anthrax outbreaks.
   
• Since anthrax can be transmitted from animals to humans, managing the disease in livestock is essential for public health. The large livestock population necessitates comprehensive strategies to prevent zoonotic transmission, thus boosting the market for anthrax treatment in the country.
   

Anthrax Treatment Market Share

The anthrax treatment industry is highly competitive characterized by the presence of several key players, including pharmaceutical companies and biotechnology firms. The competitive landscape is shaped by factors such as technological advancements, regulatory requirements, government funding, partnerships, and market dynamics. Collaboration between industry players, research institutions, and government agencies is crucial for advancing the development and availability of effective anthrax treatments.
 

Anthrax Treatment Market Companies

Prominent players operating in the anthrax treatment industry include:

• Alembic Pharmaceuticals Limited
• Almirall, LLC
• Bayer AG
• Emergent BioSolutions
• GlaxoSmithKline plc
• GC Biopharma, corp.
• Integrated Bio Therapeutics Inc.
• Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
• Paratek Pharmaceuticals, Inc.
• Pfizer Inc.
• Porton Biopharma
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
   

Anthrax Treatment Industry News:

• In April 2022, NightHawk Biosciences, acquired Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM (obiltoxaximab), a treatment for inhalation anthrax. This helped the company to tap the untapped market and generate revenue.
   
• In January 2021, Elusys Therapeutics Inc. announced its contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the supply of ANTHIM (obiltoxaximab), for use against a potential anthrax attack. This strategic initiative helped the company to enhance their customer base and revenue growth.
   

The anthrax treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Inhalation anthrax
• Cutaneous anthrax
• Gastrointestinal anthrax
• Injection anthrax

Market, By Drug Class

• Antibiotics
• Immunoglobulins
• Combination therapy

Market, By Route of Administration

• Parenteral
• Oral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa